

Attorney Docket No.: 10017.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1652

Filed: February 16, 2001

Examiner: M. Rao

For: Family 44 Xyloglucanases

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed September 5, 2002.

It is respectfully requested that the time for response to the Office Action be extended for a period of 3 months from December 5, 2002 to March 5, 2003. The required fee for the extension is estimated to be \$930.

The fee for claims has been calculated as shown below:

Total: $39 - 20 = 19 \times 18 = \342


Independent: $1 - 3 = 0 \times 84 = \$0$

Total additional fee for claims required is \$342.

Please charge the required extension and claims fees, estimated to be \$1272, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 26, 2003


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 10017.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1652

Filed: February 16, 2001

Examiner: M. Rao

For: Family 44 Xyloglucanases

FAX RECEIVED
FEB 26 2003
GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

OFFICIAL

Sir:

I hereby certify that the attached correspondence comprising:


1. Amendment Fee Transmittal (in duplicate)
2. Amendment

FAX RECEIVED
FEB 26 2003
GROUP 1600

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner M. Rao, fax number (703) 308-4242.

Respectfully submitted,

Date: February 26, 2003


Lourdes Ayala
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 10017.200-US

15C/jur
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Confirmation No: 5362

Serial No.: 09/784,554

Group Art Unit: 1652

Filed: February 16, 2001

Examiner: M. Rao

For: Family 44 Xyloglucanases

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action mailed September 5, 2002, please amend the above-identified application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE CLAIMS:

Please cancel claims 1-12, 19, 20, 22, 23 and 28 without prejudice or disclaimer. Please add new claims 33-71:

C 33. An isolated xyloglucanase, which is any of

(a) a polypeptide having an amino acid sequence that is at least 80% identical with one or more of the sequences of amino acids 40-559 of SEQ ID NO: 2, 4 or 6; and

(b) a polypeptide encoded by a DNA sequence that hybridizes to one or more of nucleotides 121-1677 of SEQ ID NO: 1, 3 or 5, under medium stringency conditions, wherein the medium stringency conditions are defined as hybridization in 5xSSC at 45°C and washing in 2xSSC at 60°C.

34. The xyloglucanase of claim 33, which has an amino acid sequence that is at least 85% identical with amino acids 40-559 of SEQ ID NO: 2.

03/06/2003 JH WASHINGTON 00000004 501701 09784554

01 FC:1253
02 FC:1202

930.00 CH

35. 342.00 The xyloglucanase of claim 34, which has an amino acid sequence that is at least 90% identical with amino acids 40-559 of SEQ ID NO: 2.